Role of (pro) renin receptor in adriamycin-induced cardiomyopathy Authors: Hui Ma, Liqin Wang, Chenggang Mao, Yang Hu, Xingqing Guo, Lei Li, Fang Wang, Renzheng Guan, Longbo Zheng Published: 2026 ABSTRACT AbstractPurpose(Pro) renin receptor (PRR) is a newly recognized element of the renin-angiotensin system associated with cardiovascular diseases. Nevertheless, the exact roles of PRR in adriamycin-induced cardiomyopathy (ADR-CM), represented as decreased heart function or symptoms or signs of heart failure, remain incompletely understood.MethodsA rat model of ADR-CM was established by intraperitoneally injecting adriamycin (ADR). Primary neonatal rat cardiomyocytes (NRCMs) and cardiac fibroblasts (NRCFs) were stimulated with ADR. PRR inhibitor PRO20 was synthesized and utilized to assess its effects on ADR-CM rats. PRR gene overexpression and silencing were achieved through transfecting recombinant adenoviruses containing PRR and PRR-shRNA in rats and cells. The ERK inhibitor PD98059 was used to suppress phosphorylated ERK1/2 (pERK1/2) in cells.ResultsPRR was significantly upregulated in ADR-CM and ADR-stimulated NRCMs and NRCFs. In vivo experiments demonstrated that PRR overexpression exacerbated ADR-induced cardiac dysfunction and myocardial hypertrophy, while systemic administration of PRO20 attenuated ADR-induced this effect. In vivo and vitro experiments, systemic PRO20 administration and PRR gene knockdown attenuated ADR-induced fibrosis, inflammatory response, apoptosis and oxidative stress, whereas PRR overexpression had the opposite effects. Inhibition of PRR decreased ADR-induced cardiac renin activity, angiotensin II (Ang II) concentration and pERK1/2 protein level, while overexpression of PRR increased these indices in the presence of ADR. PD98059 attenuated cardiomyocyte fibrosis, inflammatory response, apoptosis, and reduced NOX2 abundance and NOX activity in ADR-treated NRCFs.ConclusionPRR is involved in the pathological progression of ADR-CM, and inhibition of PRR may represent a novel and promising therapeutic strategy for ADR-CM.Keywords: (Pro) renin receptor, Adriamycin-induced cardiomyopathy, Gene therapy, PRO20, Cardiac function Introduction (Pro) renin receptor (PRR), a recently identified component of the renin-angiotensin system (RAS), is a single transmembrane protein encoded by the ATP6AP2 (ATPase, H+-transporting, and lysosomal-accessory protein 2) gene located in P11.4 of the X chromosome [1], [2]. PRR binds to prorenin and renin, promoting the non-proteolytic activation of prorenin and increasing renin activity, thus enhancing the catalytic efficiency of the conversion of angiotensinogen (AGT) to angiotensin I (Ang I) in the circulation and tissues. In the presence of sufficient angiotensin-converting enzyme (ACE) [3], PRR increases local Ang II generation and subsequently activates Ang II-dependent pathways. In addition to this classical RAS pathway, PRR acts as a key regulator of the local RAS by commanding renin activity in local tissues [4]. Moreover, the binding of prorenin and renin to PRR induces a conformational change in the proenzyme, and PRR directly binds to the C-terminal end of transcription factor promyelocytic leukemia zinc finger protein [5] and induces intracellular signal cascades, such as the mitogen-activated protein kinase (MAPK) signaling pathway [6], that are independent of Ang II. AS a result,PRR contributes to the pathological progression of various cardiovascular diseases through Ang II-dependent and independent pathways, including increased production of pro-fibrotic and pro-inflammatory factors and cell apoptosis [3]. For example,PRR inhibition by antagonists significantly reduced blood pressure and cardiac hypertrophy in rats with aortic constriction [7],whereas PRR overexpression induced atrial fibrillation via activating ERK1/2 in atrial myocardial fibroblasts [8]. Furthermore,PRR also played an important role in diabetic and alcoholic cardiomyopathy by activating the ERK signaling pathway and enhancing oxidative stress [9], [10]. Cardiomyopathy is a common disease characterized by structural and functional alterations in the heart, which are mixed in etiology [11]. Adriamycin (ADR), a well-established and highly effective antitumor agent, is widely used to treat hematogenous and solid cancers in the clinic. However, the accumulation of ADR causes severe cardiotoxic effects, leading to dilated cardiomyopathy and congestive heart failure [12]. RAS dysregulation is implicated in the development of ADR-induced cardiomyopathy. Ang II is significantly upregulated in the hearts of ADR-induced rats, which is accompanied by cardiac dysfunction [13]. ADR elevated mRNA and protein levels of the angiotensin type 1 receptor (AT1R) in a time- and dose-dependent manner in H9c2 cardiomyocytes in vitro [14] and in a rat model of cardiotoxicity [15], whereas the AT1R blockers (ARBs), telmisartan and losartan, enhanced left ventricular function in ADR-treated rats. Therefore, targeting RAS is of great significance for preventing and treating ADR-CM. A previous study indicated the increased protein level of PRR in a rat model of doxorubicin-induced heart failure [16]. However, the precise roles of PRR in ADR-CM remain incompletely understood. PRO20, an effective and specific PRR inhibitor, consists of the initial 20 amino acids of prorenin prosegment (L1PTDTASFGRILLKKMPSVR20), thereby blocking the association of prorenin and renin with PRR [17]. The main objective of this study was undertaken to investigate the role of PRR in ADR-CM with PRO20 and recombinant adenoviruses carrying PRR or PRR-shRNA. In particular, we verified the hypothesis that ADR treatment activates PRR, which promotes ADR-CM by activating the RAS and ERK1/2 signaling pathway. Materials and methods Ethics statement All experimental protocols and procedures have been approved by Ethics Committee of the Affiliated Hospital of Qingdao University and comply with the Guidelines for the Care and Use of Laboratory Animals issued by the US National Institutes of Health (NIH publication no. 8523 revised 1996). Preparation of PRR adenoviral vectors The full-length coding region of rat PRR was amplified by reverse-transcription polymerase chain reaction using the following primers: PRR, forward 5′-GCG TCG ACC GTG GCA CCA TGG CTG TGC-3′; reverse 5′-CCC AAG CTT TCA ATC CAT TCG AAT CTT CTG GTT TG-3′. As previously described, recombinant adenovirus (Ads) carrying a control transgene (EGFP) or rat PRR (PRR) was prepared using the AdMax system (Microbix Biosystems, Toronto, ON, Canada) [6], [18]. PRR shRNA construction and adenovirus generation Based on the Signaling Gateway protocol, the shRNA cassette containing PRR target sequence (GCTCCGTAATCGCCTGTTTCA) was designed. Gene-Pharma (Shanghai GenePharma Co. Ltd., Shanghai, China) designed and constructed recombinant adenoviral vectors expressing PRR shRNA. A scramble-shRNA served as the negative control. Primary neonatal rat cardiomyocytes (NRCMs) extraction Primary NRCMs were extracted from Wistar rats (1–3 days old) according to previous reports [19]. In summary, the rats' hearts were excised. Connective tissues and blood vessels around the heart and the atrium were cut off. The ventricular muscles were digested repeatedly with collagenase type 2 (LS004176, Worthinton) in Hank's balanced salt solution. The cells were harvested after centrifugation (5 min, 60 g). Pure NRCMs were obtained by differential adhesion method. Cell culture and design Primary NRCMs were resuspended in a culture medium consisting of 80% Dulbecco's Modified Eagle's Medium (DMEM, Gibco BRL, Gaithersburg), 20% fetal bovine serum (FBS, Gibco BRL, Gaithersburg), 100 U/ml penicillin and streptomycin (Gibco-BRL, Gaithersburg), and 1% BrdU (19–160, Sigma). Primary neonatal rat cardiac fibroblasts (NRCFs) were extracted from Wistar rats (3 days old) according to previous reports [20] and resuspended in DMEM supplemented with 10% FBS. Subsequently, primary NRCMs and NRCFs were cultured in a humidified incubator with 5% CO2 and 95% air at 37 °C. In the initial phase of the in vitro experiment, NRCMs were exposed to varying concentrations of ADR (Sigma, Saint Louis, USA) (0 μM, 0.1 μM, 1 μM,5 μM, 10 μM) for 24 h, and to 5 μM ADR for different durations (0 h, 2 h, 6 h, 12 h, 24 h, 48 h). The cells were harvested. In the second phase of the in vitro experiment, NRCFs were categorized into four groups: 1) control, 2) ADR, 3) ADR + SC-shRNA, and 4) ADR + PRR-shRNA. The ADR + SC-shRNA and ADR + PRR-shRNA groups underwent transfection with recombinant adenoviruses carrying SC-shRNA and PRR-shRNA for 48 h, followed by a 24-h co-treatment with 5 μM ADR. The ADR group was maintained in normal medium for 48 h before a 24-h exposure to 5 μM ADR. The control group was kept in normal medium for 72 h. Subsequently, cells and medium were collected for further analysis. In the third segment of the in vitro experiment, NRCFs were randomly divided into five groups: 1) ADR + PD98059, 2) ADR, 3) ADR + EGFP, 4) ADR + PRR, and 5) ADR + PRR + PD98059. The ADR group was incubated in normal medium for 48 h, followed by 24-h exposure to 5 μM ADR. The ADR + PD98059 group underwent the same initial incubation, with the addition of 20 μM PD98059 (Selleck, Houston, USA) to the ADR treatment for the final 24 h. The ADR + EGFP and ADR + PRR groups were transfected using recombinant adenovirus containing EGFP and PRR for 48 h, followed by a 24-h co-treatment with 5 μM ADR. The ADR + PRR + PD98059 group was transfected with recombinant adenoviruses containing PRR for 48 h, at the same time as 20 μM PD98059 was added to the ADR-treated group for 24 h. Cells and medium were collected at the experiment's conclusion. Animal protocol Male Wistar rats, aged 8–10 weeks and weighing 250–300 g, were kept in standard cages under specific pathogen-free conditions, with regular provision of food and water, and a 12-h light/dark cycle. In the initial phase of the in vivo experiment, male Wistar rats (n = 50) were administered 6 intraperitoneal injections of 2.5 mg/kg ADR over a period of 2 weeks, resulting in a total cumulative dose of 15 mg/kg body weight [21]. All rats were continued to be fed for 4 weeks. Rats were euthanized at weeks 0, 2, 4, and 6 (n = 5–7 per time point) to evaluate myocardial PRR abundance. In the second phase of the in vivo experiment, male Wistar rats were first randomly divided into 2 groups: the control group (n = 15) and the treatment group (n = 180). Sample size was determined based on power analysis using preliminary data from pilot experiments. With an expected effect size of 15% difference in left ventricular ejection fraction (LVEF) between groups, α = 0.05, and statistical power of 0.8, we estimated a minimum of 8 animals per group for the final analysis. Considering the anticipated mortality rate of approximately 30–40% in the ADR-CM model, consistent with previous reports [22]. The treatment group was used to construct ADR-CM model by 6 intraperitoneal injections of ADR within a period of two weeks according to the above method. The rats in the control group were administered an equal volume of normal saline. During the two-week ADR injection period, 13 rats in the treatment group died due to acute peritonitis or toxic systemic effects rather than a result of cardiac dysfunction [23]. Another 7 rats were excluded from further analysis due to poor general condition after modeling and failure to meet modeling criteria. Two weeks later, the remaining 160 rats in the treatment group were reseparated into the ADR-CM, ADR-CM + EGFP, ADR-CM + PRR and ADR-CM + PRO20 groups (n = 40 per group). Rats in the ADR-CM + EGFP, ADR-CM + PRR groups were anesthetized with isoflurane, securely fastened on a platform, and subjected to mechanical ventilation using a VIP Bird ventilator (Bird Products Corp., Palm Spring, CA, USA) with a tidal volume set at 3.0 ml and a respiratory rate maintained at 60 cycles per minute. Under sterile conditions, the pericardium was opened anteriorly to expose the heart. Recombinant adenoviruses containing EGFP and PRR (1 × 109 pfu each) were injected into 8–10 sites in the left ventricular free wall using a 30-gauge needle, following the method outlined previously [24], in a total volume of 200 μl. On the same day, rats in the ADR-CM and ADR-CM + PRO20 groups were anesthetized with 2% isoflurane in 1.5 L/min O2 and subcutaneously implanted with Alzet osmatic minipumps (Cupertino, California, USA) to deliver saline for the ADR-CM group or PRO20 (700μg/kg/d, dissolved in saline) for the ADR-CM + PRO20 group. All rats were kept on a standard diet for 4 weeks. All rats were euthanized under anesthesia at the experiment's conclusion. The hearts of rats were extracted for further morphological and histological analysis. Real-time quantitative PCR Total RNA was extracted from the myocardium of rats and cells using Trizol reagent (Invitrogen, Carlsbad, CA) following the manufacturer's protocol, and dissolved in RNase free water. Total RNA concentrations were quantified with a spectrophotometer. RNA was converted to cDNA with a PrimeScript RT reagent kit (Takara, Dalian, China), and the amplification of cDNA was preformed using SYBR Green PCR Master Mix (RR420A, Takara Bio Inc., Otsu, Shiga, Japan). The mRNA expression of PRR was normalized to GAPDH and presented as a fold change relative to the control. The primer sequences were listed as follows: PRR: 5′-TCTGTTCTCAACTCGCTCCC-3′ (forward) and 5′-TCTCCATAACGCTTCCCAAG-3′ (reverse), GAPDH: 5′-TCTCTGCTCCTCCCTGTTCT-3′ (forward) and 5′-ATCCGTTCACACCGACCTTC-3′ (reverse). Western blot analysis Total proteins were extracted from myocardial tissues and cells using RIPA lysis buffer (Beyotime, China) supplemented with protease inhibitor cocktail (Roche, Switzerland) and phosphatase inhibitor cocktail (Roche, Switzerland). Protein concentrations were quantified using a BCA protein assay kit (Beyotime, China). Equal amounts of protein were separated by SDS-PAGE and transferred to polyvinylidene difluoride (PVDF) membranes. The membranes were blocked with 5% skim milk at room temperature for 1.5 h, followed by an overnight incubation at 4 °C with primary antibodies: PRR, collagen I, TGF-β1, TNF-α, collagen III, ICAM-1, VCAM-1, Bax, Bcl-2, c-caspase3, NOX2, 4-HNE (all 1:1000; Abcam, UK); CTGF, IL-6, GAPDH (all 1:1000; CST, USA); and pERK1/2, ERK1/2 (both 1:800; CST, USA). After being washed, the membranes were incubated for 1 h at room temperature with horseradish peroxidase-conjugated secondary antibody (1,5000, Proteintech, Wuhan, China). GAPDH was the internal control. Immune complexes were detected using an enhanced chemiluminescence reagent (Millipore Corp., MA, USA). Body weight and blood pressure measurement After 6 weeks, the body weights (BW) of rats were recorded in the second phase of the in vivo experiment using an electronic scale (Seca Company, Germany). During the second part of the in vivo experiment, the heart rate (HR), systolic blood pressure (sBP), and diastolic blood pressure (dBP) of the rats were measured using a non-invasive tail-cuff system (Softron BP-98 A, Tokyo, Japan) by the same operator, and the measurements were recorded. All measurements were repeated 3 times. Echocardiographic imaging After 6 weeks, the rats were anesthetized using isoflurane and positioned on a heated platform. Using the Vevo2100 high-resolution imaging system (VisualSonics, Toronto, Canada), transthoracic echocardiography was performed by an echocardiographer blinded to the animal's identity. M-mode echocardiography was used to measure left ventricular ejection fraction (LVEF), fractional shortening (FS), left ventricular end-systolic diameter (LVESD) and left ventricular end-diastolic diameter (LVEDD) in the papillary muscle long axis and left ventricle section view. In the apical four-chamber view, early (E) and late (A) diastolic mitral valve flow velocities were measured using pulsed Doppler, and the E/A ratio was calculated. Histopathology and immunohistochemistry Rat hearts were freshly isolated, fixed in 10% formaldehyde solution, embedded in paraffin, and then sectioned at 4 μm thickness. After a series of xylene dewaxing and gradient alcohol dehydration, the sections were stained with hematoxylin and eosin (H&E) to examine pathological changes in the heart. The collagen content in myocardial tissue was measured by Masson's trichrome staining and expressed as the ratio of the positive area to the total left ventricular area in the sections. Protein levels of PRR, collagen I, collagen III, IL-6 and TNF-α in myocardial tissues were assessed using immunohistochemical staining. In summary, sections were initially blocked with goat serum for 15 min at 37 °C to prevent nonspecific reactions, and then incubated overnight at 4 °C with corresponding primary antibodies against PRR (1:200; Abcam), collagen I (1:100; Abcam), collagen III (1:50; Abcam), IL-6 (1:100; CST) and TNF-α (1,100; Abcam). This was followed by a 30-min incubation at 37 °C with a horseradish peroxidase-conjugated secondary antibody. The negative controls were incubated without primary antibodies. The images were visualized with a microscope (BX41, Olympus). Positive areas were quantitated with Image-Pro Plus software (Media Cybernetics Inc.). TUNEL staining Following the manufacturer's instructions for the In Situ Cell Death Detection Kit, TMR red (Roche, Germany), Apoptosis in rat myocardium was detected by TUNEL staining. In short, myocardial sections that have been dewaxed in xylene and rehydrated by reducing ethanol concentration were incubated with proteinase K working solution, and then treated in the dark at 37 °C for 1 h with a TUNEL reaction mixture containing TdT and fluorescein-labeled dUTP. Cellular nuclei were stained with DAPI (Sigma-Aldrich) for 10 min at 37 °C. Myocardial samples were analyzed under a fluorescence microscope with an excitation wavelength. TUNEL-positive apoptotic cells and total cells were counted, while the ratio was calculated. SOD activity, MDA content and NOX activity assay Superoxide dismutase (SOD) activity in rat myocardium was determined using an assay kit (Nanjing Jiancheng Biotech, China) following the manufacturer's protocol. Malondialdehyde (MDA) content in rat myocardium was measured using an assay kit (Nanjing jiancheng Biotech, China) based on the thiobarbituric acid (TBA) reaction. Briefly, myocardial tissue homogenates were mixed with TBA reagent, heated at 95 °C for 40 min, and cooled to room temperature. After centrifugation, the absorbance of the supernatant was measured at 532 nm. MDA content was calculated according to a standard curve and expressed as nmol/mg protein. Nicotinamide adenine dinucleotide phosphate oxidase (NOX) activity in rat myocardium and cells was evaluated using a kit from Solarbio, Beijing, China, following the manufacturers' protocols. Enzyme linked immunosorbent assay (ELISA) The concentration of Ang II in the rat myocardium was measured using commercial ELISA kits (Bachem, USA) according to the manufacturer's recommendations [25]. The protein levels of IL-6, TNF-α, TGF-β and soluble collagen I in cell supernatants were quantified using ELISA kits (Abcam, Cambridge, MA) following the manufacturer's guidelines. All sample analyses were repeated 3 times. Renin activity assay Renin activity in the rat myocardium were performed as described previously [26]. Briefly, cardiac tissue samples were centrifuged at 4,000 rpm for 20 min at 4 °C to collect the supernatant. After a 1 h incubation at 37 °C versus 4 °C, renin activity was determined by the delta value of the Ang I generation using an ELISA kit (S-1188, Peninsula Laboratories). Cardiac renin activity was expressed as Ang I ng/h/g protein. Statistical analysis Data were presented as the mean ± standard error (SEM) and analyzed using SPSS 21.0 (SPSS Inc., Chicago, IL). Normality of distribution was assessed using the Shapiro-Wilk test. For data that followed a normal distribution, parametric comparisons among more than two groups were performed using one-way ANOVA followed by Tukey's honestly significant difference post hoc test. For data that deviated from normality,for collagen levels and relative expression level, logarithmic transformation (log10) was applied prior to ANOVA to approximate normality. As an additional validation, non-parametric analysis using the Kruskal-Wallis test followed by Dunn's post hoc test was performed for key comparisons, which yielded results consistent with the parametric analyses. *. Kaplan-Meier survival curves were compared using the log-rank with mantel-cox test. P value <0.05 was considered statistically significant. Results PRR abundance was increased in ADR-stimulated NRCMs and rat heart tissues Initially, NRCMs were exposed to varying ADR concentrations. Real-time quantitative PCR and western blot analyses demonstrated a concentration-dependent increase in PRR mRNA and protein level following ADR treatment (Fig. 1A–B). Secondly, NRCMs were treated with 5 μm ADR for different durations. The results showed that ADR stimulation upregulated PRR abundance over time. In addition, 24 h after ADR stimulation, PRR abundance peaked (Fig. 1C–D). PRR abundance in ADR-stimulated NRCMs and rat heart tissues. (A) PRR mRNA expression was examined by real-time quantitative PCR and (B) representative western blot images and quantification of PRR protein level in NRCMs treated with different concentrations of ADR. (C) PRR mRNA expression and (D) representative Western blot images and quantification of the levels of PRR protein level in NRCMs treated with 5 μm ADR for different times. Mean values were derived from five independent experiments. Data were expressed as individual data points with bars representing mean ± SEM. *P < 0.05 vs 0 μM (or 0 h) group. (E) Representative immunohistochemical staining of PRR in the rat myocardium at different time points. Scale bar = 20 μm. (F) Quantitative analysis of positive PRR staining. (G) PRR mRNA expression in the rat myocardium at different time points. N = 5 in each group. Data were reported as individual data points with bars representing mean ± SEM. *P < 0.05 vs Week 0 group. In vivo analysis of PRR abundance in heart tissues of ADR-treated rats, assessed through immunofluorescence staining and real-time quantitative PCR at various time points, revealed a progressive increase (Fig. 1E–G). Body weight, blood pressure and mortality in the five groups of rats Compared to the control group, ADR treatment significantly reduced both body weight and blood pressure in all four treatment groups. However, Neither PRR overexpression via adenoviruses nor PRO20 treatment affected body weight and blood pressure compared to the ADR-CM and ADR-CM + EGFP groups (Table 1). Additionally, there were no significant differences in heart rates among the five groups. Table 1Animal basic characteristics in five groups of rats.GroupsControlADR-CMADR-CM + EGFPADR-CM + PRRADR-CM + PRO20HR (bmp)353.07 ± 13.46349.63 ± 21.87365.28 ± 16.32362.93 ± 20.11358.74 ± 11.57BW (g)576.94 ± 29.63393.04 ± 21.38⁎386.33 ± 15.38⁎367.94 ± 24.75⁎416.51 ± 18.02⁎sBP (mmHg)126.83 ± 4.4286.92 ± 1.73⁎80.75 ± 3.51⁎83.03 ± 3.91⁎84.30 ± 4.12⁎dBP (mmHg)98.76 ± 1.1963.17 ± 2.04⁎65.20 ± 1.38⁎59.55 ± 2.87⁎63.44 ± 1.58⁎HR, heart rate; BW, body weight; sBP, systolic blood pressure; dBP, diastolic blood pressure. Data were expressed by mean ± SEM. N = 6–15 in each group. *P < 0.05 vs Control. Animal basic characteristics in five groups of rats. HR, heart rate; BW, body weight; sBP, systolic blood pressure; dBP, diastolic blood pressure. Data were expressed by mean ± SEM. N = 6–15 in each group. *P < 0.05 vs Control. Out of 180 rats in the treatment group, 13 died during the injection of ADR, which was excluded from the survival calculation, as the mortality at this stage was attributed to peritonitis or toxic systemic effects rather than a result of cardiac dysfunction [23]. During the 4-week period after the initial adenoviral myocardial injection and PRO20 administration, cumulative mortalities were observed as follows: 0% in the control group (0 deaths), 65% in the ADR-CM group (26 deaths), 62.5% in the ADR-CM + EGFP group (25 deaths), 85% in the ADR-CM + PRR group (34 deaths), and 37.5% in the ADR-CM + PRO20 group (15 deaths) (Fig. 2). Compared with that in the control group, mortality was significantly increased in the ADR-CM and ADR-CM + EGFP groups, and was further increased in ADR-CM rats injected with the adenoviruses containing PRR. However, PRO20 administration significantly decreased the mortality of ADR-treated rats. Kaplan-Meier survival curves in the five groups of rats. Survival rate was observed over a 4-week period following the initial adenoviral myocardial injection and PRO20 administration, and analyzed by the Kaplan-Meier survival curves. *P < 0.05 vs Control. &P < 0.05 vs ADR-CM + EGFP. #P < 0.05 vs ADR-CM. Role of PRR in ADR-induced left ventricular dysfunction and myocardial hypertrophy At the end of 6 weeks, left ventricular function parameters in the five groups of rats were detected by echocardiography. Compared to the control group, the ADR-CM and ADR-CM + EGFP groups exhibited significantly increased LVESD and LVEDD, while LVEF, FS, and the ratio of early to late diastolic mitral inflow velocities (E/A) decreased (Fig. 3A–F). Furthermore, compared to the ADR-CM + EGFP group, PRR overexpression further exacerbated cardiac dysfunction in the ADR-CM + PRR group. In contrast, treatment with PRO20 for 4 weeks led to a reduction in LVESD and LVEDD, while enhancing LVEF, FS, and E/A compared to the ADR-CM group. No statistically significant difference was observed between the ADR-CM and ADR-CM + EGFP groups. Role of PRR in ADR-induced left ventricular dysfunction and myocardial hypertrophy in the five groups of rats. (A) Representative echocardiographic images in the five groups of rats: two-dimensional echocardiograms showing left ventricular long-axis view and M-mode echocardiograms showing left ventricular dimensions. (B—F) Statistical results: LVEF, FS, LVEDD, LVESD, and E/A radio. LVEF, left ventricular ejection fraction; ES, left ventricular fractional shortening; LVESD, left ventricular end-systolic diameter; LVEDD, left ventricular end-diastolic diameter; E/A ratio: ratio of the early to late diastolic mitral inflow velocities. (G) Representative H&E staining of myocardial cross-sections in the five groups of rats. Scale bar = 20 μm. (H) Quantitative analysis of cardiomyocytes size in five groups of rats. N = 5–15 in each group. Data was shown as individual data points with bars representing mean ± SEM. *P < 0.05 vs Control. &P < 0.05 vs ADR-CM + EGFP. #P < 0.05 vs ADR-CM. Morphologically, H&E staining showed that rats in the ADR-CM and ADR-CM + EGFP groups exhibited marked myocardial structure disturbances, which were accompanied by increased cardiomyocyte size, compared with rats in the control group (Fig. 3G–H). PRR overexpression caused more severe pathological changes in myocardial morphology whereas inhibition PRR with PRO20 reversed ADR-induced these abnormalities in rats. Role of PRR in ADR-induced myocardial fibrosis and inflammatory response Masson's trichrome staining revealed that the collagen contents in the myocardium were significantly increased in the ADR-CM and ADR-CM + EGFP groups compared to the control group, with an even greater increase observed in the ADR-CM + PRR group relative to the ADR-CM + EGFP group (Fig. 4A–B). In contrast, PRO20 treatment decreased collagen contents in the myocardium in ADR-induced rats. Similarly, immunohistochemical staining and Western blot analysis showed that the levels of collagen I and collagen III in the myocardium was significantly upregulated in the ADR-CM and ADR-CM + EGFP groups compared to the control group. This upregulation was enhanced by PRR overexpression and reduced by PRO20 administration (Fig. 4A, C–E). Collagen content in the ADR-CM and ADR-CM + EGFP groups was not significantly different. Connective tissue growth factor (CTGF) and transforming growth factor-β (TGF-β) are important factors that regulate collagen production. The expression trends of CTGF and TGF-β proteins in the five rat groups mirrored those of collagen (Fig. 4E–G). Role of PRR in ADR-induced myocardial fibrosis in the five groups of rats. (A) Representative Masson's trichrome staining, and immunohistochemical staining of collagen I and collagen III in the myocardium in the five groups of rats. Scale bar = 20 μm. (B—D) Quantitative analysis of positive staining for collagen, collagen I and collagen III in the five groups of rats. (E) Representative western blot images of the protein levels of collagen I, collagen III, CTGF and TGF-β1 in the myocardium in the five group of rats. (F and G) quantitative analysis of CTGF and TGF-β1 protein levels in five groups of rats. N = 5 in each group. Data were expressed as individual data points with bars representing mean ± SEM. *P < 0.05 vs Control. &P < 0.05 vs ADR-CM + EGFP. #P < 0.05 vs ADR-CM. Inflammatory response in the myocardium is a pathological feature of ADR-CM [27]. In this study, the level of inflammatory cytokines was detected to compare the inflammatory status in the five groups of rats. ICAM-1 and VCAM-1 protein levels in the myocardium were prominently increased in the ADR-CM and ADR-CM + EGFP groups compared to the control group, as shown by immunohistochemical staining and western blot, and the elevation in the levels of these inflammatory cytokines was further upregulated following treatment with PRR-containing adenoviruses (Fig. 5). In contrast, inhibition of PRR by PRO20 notably reduced the protein levels of IL-6, TNF-α, ICAM-1 and VCAM-1 induced by ADR treatment. Likewise, the ADR-CM and ADR-CM + EGFP groups showed no significant differences. Role of PRR in ADR-induced inflammatory response in the five groups of rats. (A) Representative immunohistochemical staining of IL-6 and TNF-α in the myocardium in the five groups of rats. Scale bar = 20 μm. (B—C) Quantitative analysis of the positive staining for IL-6 and TNF-α in the five group of rats. (D) Representative western blot images of IL-6, TNF-α, ICAM-1 and VCAM-1 protein levels in the myocardium in the five groups of rats. (E-F) Quantitative analysis of ICAM-1 and VCAM-1 protein levels in five group of rats. N = 5 in each group. Data were shown as individual data points with bars representing mean ± SEM. *P < 0.05 vs Control. &P < 0.05 vs ADR-CM + EGFP. #P < 0.05 vs ADR-CM. Role of PRR in ADR-induced myocardial apoptosis and oxidative stress In order to evaluate the action of PRR in cardiomyocyte apoptosis, TUNEL staining was performed to quantitate the proportion of TUNEL-positive apoptotic cells in the myocardium. The heart tissues in the control group had only a small number of TUNEL-positive cells. Furthermore, a relatively higher number of apoptotic cells were observed in the ADR-CM and ADR-CM + EGFP groups, with the proportion of TUNEL-positive apoptotic cells being significantly higher compared to the control group (Fig. 6A–B). Compared to the ADR-CM and ADR-CM + EGFP groups, PRR overexpression further increased apoptotic cell numbers, while PRO20-mediated PRR inhibition reduced the number of apoptotic cells. However, there was no statistical significance between the ADR-CM group and the ADR-CM + EGFP group. To further assess the impact of PRR on cardiomyocyte apoptosis, protein levels of Bax, Bcl-2, and C-caspase-3 were examined through Western blot analysis. The results showed that the Bax/Bcl-2 protein ratio and C-caspase-3 protein level were significantly upregulated in the ADR-CM and ADR-CM + EGFP groups compared to the control group (Fig. 6C–E). Moreover, PRR overexpression exacerbated myocardial apoptosis, while PRO20 treatment alleviated ADR-induced myocardial apoptosis in rats. Role of PRR in ADR-induced apoptosis and oxidative stress in the five groups of rats. (A) Representative TUNEL-positive cardiomyocyte staining in the myocardium in the five groups of rats. Scale bar = 20 μm. (B) Quantification of TUNEL-positive cardiomyocytes in the five groups of rats. (C) Representative Western blot images of Bax, Bcl-2 and C-caspase-3 protein levels in myocardium in the five groups of rats. (D-E) Quantification of Bax/Bcl-2 and C-caspase-3 protein levels in the five groups of rats. (F) Representative western blot analysis of NOX2 and 4-HNE protein levels in the myocardium in the five groups of rats. For the 4-HNE immunoblot in panel F: based on the mitochondrial injury mechanism of doxorubicin, only the 50–60 kDa membrane fragment was collected for exposure; full-length original blots were not preserved. Two bands were detected within this region: a dominant upper band at ∼57 kDa and a weaker lower band at ∼52 kDa. Quantification was performed exclusively on the stable, reproducible ∼57 kDa band. The ∼52 kDa band was not quantified due to weak signal and poor reproducibility. (G-H) Quantitative analysis of NOX2 and 4-HNE protein levels in the five groups of rats. (I-G) Measurement of SOD and MDA levels in the myocardium. (K) The levels of NOX activity in the myocardium. N = 5 in each group. Data were expressed as individual data points with bars representing mean ± SEM. *P < 0.05 vs Control. &P < 0.05 vs ADR-CM + EGFP. #P < 0.05 vs ADR-CM. Oxidative stress levels in the myocardium were assessed across five rat groups, showing notable increases in NOX2 and 4-HNE protein levels, MDA content, and NOX activity, alongside a significant decrease in SOD activity in the ADR-CM and ADR-CM + EGFP groups compared with those in the control group (Fig. 6F–K). In contrast, the levels of oxidative stress in the ADR-CM group and ADR-CM + EGFP group were not significantly different. PRR overexpression further exacerbated ADR-induced these abnormalities in rats. However, these abnormalities induced by ADR were effectively normalized by treatment with PRO20. Role of PRR in ADR-induced cardiac RAS activation and ERK1/2 signaling pathway We explored the potential regulation of cardiac RAS and ERK1/2 signaling pathways by PRR in ADR-treated rats. The ADR-CM and ADR-CM + EGFP rat models exhibited increased cardiac PRR mRNA and protein levels relative to the control group (Fig. 7A–E). These levels were further enhanced by transfection with adenoviruses containing PRR but remained unchanged with PRO20 treatment. Similarly, cardiac renin activity and Ang II concentration was significantly increased in the ADR-CM and ADR-CM + EGFP groups (Fig. 7F–G). PRR overexpression elevated ADR-induced cardiac renin activity and Ang II concentration, both of which were reduced by PRO20 treatment. These data indicate that PRR is essential for ADR-induced cardiac RAS activation. Role of PRR in ADR-induced cardiac RAS activation and phosphorylated ERK1/2 protein level in the five groups of rats. (A) Representative immunohistochemical staining of PRR in the myocardium in the five groups of rats. Scale bar = 20 μm. (B) Quantitative analysis of the positive PRR staining. (C) PRR mRNA expression in the myocardium was assayed by real time PCR in the five groups of rats. (D) PRR protein level in the myocardium was analyzed by western blot in five groups of rats. (E) Quantitative analysis of PRR protein level in the five groups of rats. (F) Renin activity in the myocardium. (G) Ang II concentration in the myocardium were detected by ELISA. (H) Representative Western blot images of the protein levels of pERK1/2 and ERK1/2 in the myocardium and quantification of pERK/ERK in the five groups of rats. N = 5 in each group. Data were expressed as individual data points with bars representing mean ± SEM. *P < 0.05 vs Control. &P < 0.05 vs ADR-CM + EGFP. #P < 0.05 vs ADR-CM. ERK1/2, part of the MAPK family, is involved in the pathogenesis of ADR-CM [28]. In this study, the level of phosphorylated ERK1/2 (pERK1/2) protein was prominently increased in the ADR-CM and ADR-CM + EGFP groups compared to the control group, with an additional increase observed in the ADR-CM + PRR group relative to the ADR-CM + EGFP group (Fig. 7H). On the other hand, compared with that in the ADR-CM groups, PRO20 treatment reversed the effect of ADR and reduced the level of pERK1/2. No statistically significant difference was found between the ADR-CM and EGFP groups. PRR knockdown eliminated ADR-enhanced fibrosis, inflammation, apoptosis, oxidative stress and pERK1/2 level in NRCFs To further evaluate PRR's involvement in ADR-induced fibrosis, inflammation, apoptosis, oxidative stress and pERK1/2 level in NRCFs, endogenous expression of PRR was suppressed by transfecting adenoviruses containing PRR-shRNA (Fig. 8A–B). The study measured expression levels of markers associated with fibrosis (collagen I, TGF-β), apoptosis (C-caspase-3), oxidative stress (NOX2, NOX activity), inflammatory cytokines (IL-6, TNF-α), and pERK1/2 protein. These indices in cardiac fibroblasts were significantly increased in the ADR and ADR + SC-shRNA groups compared to the control group, but were downregulated due to the knockdown of PRR (Fig. 8A, C–J), which was consistent with the in vivo results. These results suggest that PRR knockdown effectively counteracted ADR-mediated fibrosis, inflammation, apoptosis, oxidative stress and ERK level in NRCFs. PRR knockdown attenuated ADR-enhanced fibrosis, inflammation, apoptosis, oxidative stress and ERK level in NRCFs. (A) Representative western blot analysis of PRR, NOX2, C-caspase-3, pERK1/2 and ERK1/2 protein levels in NRCFs after gene therapy. (B-E) Quantitative analysis of PRR, NOX2, C-caspase-3 protein levels and pERK/ERK in NRCFs. (F) The levels of NADPH oxidase activity in NRCFs. (G-J) ELISA analysis of collagen I, TGF-β, IL-6 and TNF-α expression levels in NRCFs. Five independent experiments were performed to derive the mean values. Data were shown as individual data points with bars representing mean ± SEM. *P < 0.05 vs Control. &P < 0.05 vs ADR and ADR + SC-shRNA. ADR-induced fibrosis, inflammation, apoptosis and increased NOX2 abundance and NOX activity were mediated by the PRR-ERK1/2 pathway in NRCFs To further assess whether PRR exerted its effects in the context of ADR via the PRR-ERK1/2 signaling pathway. NRCFs in the context of ADR were treated with the ERK inhibitor PD98059 and adenoviruses containing PRR. In cardiac fibroblasts, the protein level of pERK1/2 was suppressed by PD98059 (Fig. 9A) and PRR protein level was substantially increased by transfection of adenoviruses containing PRR (Fig. 9B). Moreover, PD98059 inhibited the ADR-induced upregulation of fibrosis markers (collagen I, TGF-β), apoptosis marker (C-caspase-3), NOX2 abundance and NOX activity, and inflammatory cytokines (IL-6, TNF-α) in NRCFs (Fig. 9B–I). In addition, PRR overexpression further aggravated ADR-induced fibrosis, inflammation, apoptosis and the increase in NOX2 abundance and NOX activity in NRCFs (Fig. 9B–I), while PD98059 reversed these effects induced by PRR overexpression in ADR-treated cells. These results suggest that ADR-induced fibrosis, inflammation, apoptosis and increased NOX2 abundance and NOX activity may be mediated by the PRR-ERK1/2 pathway in NRCFs. ADR-induced fibrosis, inflammation, apoptosis and increased NOX2 abundance and NOX activity may be mediated by the PRR-ERK1/2 pathway in NRCFs. (A) Representative Western blot images of pERK1/2 and ERK1/2 protein levels and quantification of pERK/ERK in the five groups of NRCFs. (B) Representative Western blot images of the protein levels of PRR, NOX2 and C-caspase-3 in the five groups of NRCFs. (C—D) Quantitative analysis of NOX2 and C-caspase-3 protein levels in the five groups of NRCFs. (E) The levels of NADPH oxidase activity in five groups of NRCFs. (G-J) ELISA analysis of collagen I, TGF-β, IL-6 and TNF-α expression levels in the five groups of NRCFs. Oxidative stress in this experimental series was assessed by NOX2 abundance and NOX activity; direct markers of oxidative stress such as 4-HNE adduct formation or intracellular ROS levels were not examined. Mean values were measured by five independent experiments. Data were presented as individual data points with bars representing mean ± SEM. *P < 0.05 vs ADR. &P < 0.05 vs ADR + EGFP. #P < 0.05 vs ADR + PRR. Discussion This study highlights the significance and novel aspects of PRR in the progression of ADR-induced cardiac dysfunction and remodeling. We demonstrated that systemic PRO20 administration and knockdown PRR by transfecting adenoviruses containing PRR-shRNA alleviated ADR-induced fibrosis, inflammation, apoptosis and oxidative stress by inhibiting the RAS and ERK1/2 signaling pathway in vivo and in vitro (Fig. 10). These findings suggested that inhibiting PRR may represent a novel and promising therapeutic strategy for ADR-CM. Schematic structure diagram of the mechanism. PRR activation in ADR-CM contributes to cardiac injury through dual pathways: (1) an Ang II-dependent pathway involving activation of the cardiac RAS (increased renin activity and Ang II concentration), and (2) an Ang II-independent pathway involving activation of the ERK1/2 signaling. These pathways collectively promote myocardial fibrosis, inflammation, apoptosis, and oxidative stress, leading to cardiac dysfunction and remodeling. PRO20 treatment and PRR knockout alleviates these pathological effects. PRR, initially cloned and named by Nguyen in 2002 [1], is extensively expressed in multiple organs such as heart, blood vessels, kidney and brain [29]. The gene encoding PRR is also known as ATP6AP2, because PRR is viewed as an accessory subunit of vacuolar H+-ATPase (V-ATPase), serving as a crucial chaperon for V-ATPase subunits assembly [30]. Although PRR did not directly influence the activity of intact V-ATPases [31], its essential role is underscored by findings that cardiomyocyte-specific PRR knockout impairs V-ATPase assembly and blocks autophagic flux, resulting in severe heart failure [32]. Beyond its role in V-ATPase function, PRR participates in multiple signaling pathways relevant to cardiovascular pathology. PRR exerts its effects through both Ang II-dependent and Ang II-independent mechanisms. Moreover, PRR acts as a bridging protein between V-ATPase and low-density lipoprotein receptor-related protein 6 (LRP6), serving as a component of the Wnt receptor complex and participating in Wnt/β-catenin pathway signal transduction [33]. This pathway has been implicated in various cardiovascular processes; for instance, soluble PRR increases blood pressure by binding both LRP6 and frizzled-8 to activate wnt/β-catenin signaling in Ang II-infused animals [34], and PRR mediates hypoxia/reoxygenation-induced apoptosis and autophagy in cardiomyocytes through activating β-catenin signaling pathway [35]. In addition, the concentration of soluble plasma PRR reflects the severity of heart failure [36]. Collectively, these studies indicate that elevated PRR serves as a pathological marker of cardiac injury and represents a potential therapeutic target for cardiovascular diseases. Clinically, the most difficult condition to predict and manage is the development of ADR-CM, which ultimately leads to congestive heart failure [12], [37]. At present, the exact mechanism of ADR-CM is still elusive [38]. The mechanisms of ADR-CM are generally believed to be a combination of multiple factors that influence each other to form a malignant network and jointly promote the occurrence and development of ADR-CM. These factors include oxidative stress, lipid peroxidation, apoptosis, ferroptosis, mitochondrial damage, abnormal energy metabolism, inflammatory response, and calcium dysregulation [39], [40], [41]. Until recently, ADR-induced myocardial injury is considered as the key mechanism with the influence of reactive oxygen species (ROS) and topoisomerase-II β as the key factors leading to it [37]. Thus, many scholars are trying to solve the problem of ADR-CM pathogenesis and find effective prevention and treatment strategies. RAS dysregulation is suggested to significantly contribute to the development of ADR-CM. PRR, as a key member of the RAS, was found to be highly expressed in ADR-treated rats [16]. Our findings align with the report, demonstrating a gradual upregulation of PRR abundance in the myocardium with prolonged ADR treatment. In addition, ADR stimulation upregulated PRR abundance in cardiomyocytes, dependent on both concentration and time. These results suggest that PRR is closely related to ADR-CM. The current study reported that PRR overexpression exacerbated left ventricular dysfunction and myocardial fibrosis in ADR-CM model rats, while PRO20 administration improved cardiac function and remodeling. Myocardial fibrosis is characterized by an imbalance in the production and degradation of extracellular matrix, which can lead to cardiac dysfunction. Irrespective of etiology, injury to the heart causes a persistent fibrotic response, leading to left ventricular remodeling and dysfunction [42]. Our results revealed that PRR overexpression upregulated collagen I, collagen III, CTGF and TGF-β levels in vivo and in vitro, and these changes were inhibited by PRO20 treatment, which is in line with a previous report [10]. This previous report showed that PRR gene therapy induced the production of collagen, CTGF and TGF-β via activating the ERK signaling pathway in alcoholic cardiomyopathy model rats. In contrast, the present study employed an ADR-CM model. Notably, our work extends these findings by demonstrating that PRR knockdown and pharmacological inhibition with PRO20 protect against ADR-CM, reduce mortality, and link PRR to cardiac renin activity, Ang II generation, and ERK1/2 signaling. We further confirm that ADR directly upregulates PRR in a concentration- and time-dependent manner. Thus, PRR represents a promising therapeutic target for ADR-CM. Inflammatory response and the loss of cardiomyocytes through apoptosis can destroy heart structure, induce extracellular matrix deposition, and eventually lead to the deterioration of cardiac dysfunction, adverse cardiac remodeling and heart failure [43], [44]. A previous study reported that PRR overexpression exacerbated inflammatory response and apoptosis in an animal model of diabetic cardiomyopathy, and these pathological changes were suppressed by PRR silencing [45]. The study's in vivo and in vitro results corroborate this finding. We found that PRR overexpression with adenoviruses containing PRR increased the levels of inflammatory cytokines, TUNEL-positive apoptotic cells and apoptotic-related proteins in the myocardium of ADR-treated rats and ADR-stimulated cardiac fibroblasts, and these effects were inhibited by PRO20 treatment and PRR knockdown. Therefore, PRR may mediate ADR-induced inflammatory response and apoptosis. Oxidative stress is the primary mechanism extensively researched in relation to ADR-CM. ADR disrupted the balance between ROS production and antioxidants, resulting in oxidative stress and cardiac dysfunction [46]. Nicotinamide adenine dinucleotide phosphate oxidase (NOX), as a common source of oxidative stress, can generate ROS and participate in many kinds of cardiovascular diseases. Therefore, the mechanism of oxidative stress in cardiovascular diseases has been investigated. Our study demonstrated that PRR overexpression elevated the protein level of NOX2 in ADR-CM rats, which was accompanied by increased 4-hydroxynonenal (4-HNE) level, indicating cardiac protein lipid peroxidation. In addition, MDA content was regulated and SOD activity was downregulated in the myocardium after PRR overexpression. PRO20 treatment reduced oxidative stress damage in the myocardium of ADR-treated rats by inhibiting PRR. The same results were also obtained in ADR-treated cardiac fibroblasts by transfecting adenoviruses containing PRR-shRNA. Thus, the influence of PRR on myocardial injury in ADR-CM may be seemingly facilitated through oxidative stress. Binding of prorenin to PRR leads to the unfolding of prosegment covering the active site of prorenin, thereby exposing the enzymatic cleft. Non-proteolytically activated prorenin can locally convert AGT into Ang I, leading to the production of Ang II and activation of the tissue RAS [3]. In this study, ADR-treated mice exhibited significant increases in myocardial PRR abundance, cardiac renin activity, and Ang II concentration. Additionally, PRR overexpression enhanced ADR-induced cardiac renin activity and Ang II concentration, both of which were reduced by PRO20 treatment. These findings indicate that heart tissue RAS activation in the current ADR-CM rat model partially relied on PRR modulation. PRR can activate ERK1/2 in multiple cell types [47]. Activation of ERK1/2 induced by PRR increased the production of ROS and collagen deposition, subsequently resulting in left ventricular dysfunction and remodeling [10]. Previous studies have showed that ERK1/2 was involved in the pathogenesis of ADR-induced cardiotoxicity and associated with inflammatory response, ROS generation and apoptotic signaling [48], [49], [50], [51]. Ang II, via AT1R, activates ERK signaling pathway to be involved in doxorubicin-induced myocardial injury [52]. In our study, ADR stimulation upregulated phosphorylated ERK1/2 protein level, which is consistent with previous study. PRR overexpression further increased ERK1/2 phosphorylation in the context of ADR treatment, while PRO20 treatment significantly ameliorated this effect. In addition, administration of PD98059, an ERK kinase inhibitor, suggests that ERK1/2 plays a crucial role in ADR-induced fibrosis, inflammation, apoptosis and increased NOX2 abundance and NOX activity in cardiac fibroblasts. Furthermore, PD98059 mitigated the enhancement of these pathological responses in ADR-treated cardiac fibroblasts that was exacerbated by the overexpression of PRR. Collectively, these findings suggest that PRR may contribute to ADR-CM at least in part through activation of the RAS and ERK1/2 signaling pathways. However, it remains to be determined whether ERK1/2 activation is a direct downstream consequence of PRR signaling or a secondary effect of overall myocardial injury and oxidative stress. Additionally, the precise contribution of Ang II/AT1R signaling to PRR-mediated effects warrants further investigation. A recent study by Du et al. demonstrated that PRR is upregulated in doxorubicin-induced heart failure and that PRR inhibition mitigates doxorubicin-induced cardiac injury and oxidative stress [16]. Our study both confirms and significantly extends these findings. While Du et al. focused primarily on oxidative stress, we demonstrate that PRR inhibition also ameliorates myocardial fibrosis, inflammation, and apoptosis. Mechanistically, we show that PRR activates both the cardiac RAS and the ERK1/2 signaling pathway, a dual mechanism not previously reported. Additionally, using PRR overexpression and knockdown strategies, we provide gain- and loss-of-function evidence establishing the causal role of PRR in ADR-CM, and we further elucidate cell-type-specific contributions in cardiac fibroblasts. Collectively, our study identifies PRR-mediated dual activation of the RAS and ERK1/2 signaling pathways as a key mechanistic mechanism in ADR-CM. In summary, PRR is involved in the pathological progress of ADR-induced cardiomyopathy, and systemic PRO20 administration and PRR knockout attenuated ADR-induced fibrosis, inflammation, apoptosis and oxidative stress, suggesting involvement of the RAS and ERK1/2 signaling pathway. Limitations: First, the ADR-induced cardiomyopathy model is associated with high mortality, particularly in the PRR overexpression group. Such high attrition may introduce potential survivor bias in functional and histological analyses, as surviving animals may represent a subgroup with less severe cardiac injury. This could lead to an underestimation of the true pathological effects of PRR overexpression. Second, systemic administration of PRO20 and global PRR overexpression/knockdown cannot fully distinguish direct cardiac effects from indirect systemic or multi-organ effects, including cardiorenal interactions. The lack of cardiac-specific PRR manipulation and renal phenotyping (e.g., renal function, renal RAS activity) limits the spatial resolution of PRR action in this study. Third, our study mainly reveals correlative associations among PRR, cardiac RAS activation, and ERK1/2 phosphorylation. The causal requirement of Ang II/AT1 signaling for PRR-mediated effects was not directly tested, and we cannot exclude that ERK1/2 activation may occur secondarily to myocardial injury or oxidative stress. Thus, the proposed linear PRR–RAS–ERK pathway is supported mainly by correlation rather than definitive epistasis-based evidence. Fourth, while our results suggest that PRR acts in part through Ang II–dependent pathways, PRR also exerts Ang II–independent effects (e.g., direct activation of ERK1/2). Therefore, although AT1R antagonists would likely attenuate ADR-induced cardiac remodeling, they may not fully recapitulate the protective effects of PRR inhibition due to the Ang II-independent component. Fifth, in the in vitro experiments shown in Fig. 9, oxidative stress was primarily evaluated based on NOX2 abundance and NOX activity. Since NOX2 is only one component involved in oxidative stress, a direct marker such as 4-HNE was not included, which limits the strength of the conclusion regarding reduced oxidative stress. Sixth, full-length original 4-HNE blots were not preserved. Based on doxorubicin's mitochondrial toxicity mechanism, only the 50–60 kDa membrane fragment was retained for exposure. Two bands (∼57 kDa and ∼ 52 kDa) were detected; quantification was performed only on the stable ∼57 kDa band, while the weaker ∼52 kDa band was excluded due to poor reproducibility. 4-HNE adducts outside this molecular range could not be assessed. Future studies employing epistatic approaches, such as combined inhibition of PRR and AT1R or PRR and ERK1/2, along with cardiac-specific PRR models and comprehensive oxidative stress assessments, will help clarify the relative contributions of Ang II-dependent and independent signaling and strengthen mechanistic conclusions. CRediT authorship contribution statement Hui Ma: Writing – review & editing, Writing – original draft, Funding acquisition, Data curation, Conceptualization. Liqin Wang: Writing – review & editing, Writing – original draft, Data curation. Chenggang Mao: Writing – review & editing, Writing – original draft, Data curation, Conceptualization. Yang Hu: Writing – review & editing, Writing – original draft, Data curation. Xingqing Guo: Writing – review & editing, Writing – original draft, Data curation. Lei Li: Writing – review & editing, Writing – original draft, Data curation. Fang Wang: Writing – review & editing, Writing – original draft, Data curation. Renzheng Guan: Writing – review & editing, Writing – original draft, Data curation. Longbo Zheng: Writing – review & editing, Writing – original draft, Data curation, Conceptualization. Ethics approval All experimental protocols and procedures have been approved by Ethics Committee of the Affiliated Hospital of Qingdao University and comply with the Guidelines for the Care and Use of Laboratory Animals issued by the US National Institutes of Health (NIH publication no. 8523 revised 1996). Funding This project received support from the National Natural Science Foundation of China (No. 82300389), the Natural Science Foundation of Shandong Province (ZR2021QH073) and the Clinical Medicine + X Scientific Research Program of the Affiliated Hospital of Qingdao University (QDFY + X202101045). Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Acknowledgement We would like to thank all participators for their support and contributions in the present study. Contributor Information Renzheng Guan, Email: grz0051@qdu.edu.cn. Longbo Zheng, Email: zhenglongbo2021@qdu.edu.cn. References